EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Safety and Immunogenicity of Radiation-Attenuated PfSPZ Vaccine in Equatoguinean Infants, Children, and Adults

Said A Jongo, Vicente Urbano Nsue Ndong Nchama, L W Preston Church, Ally Olotu, Stephen R Manock, Tobias Schindler, Ali Mtoro, Natasha Kc, Orrin Devinsky, Elcin Zan, Ali Hamad, Elizabeth Nyakarungu und 33 weitere

The American Journal of Tropical Medicine and Hygiene · 05.07.2023 · 109 (1) · 138-146

DOI: 10.4269/ajtmh.22-0773 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The American Journal of Tropical Medicine and Hygiene, erschienen am 05.07.2023. Verfasst von Said A Jongo und 44 weiteren Autor:innen. Beteiligte Einrichtung: Ifakara Health Institute, Bagamoyo Research and Training Centre, Bagamoyo, Tanzania. Hauptthemen laut MEDLINE: Malaria, Falciparum, Malaria Vaccines. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The radiation-attenuated Plasmodium falciparum sporozoites (PfSPZ) Vaccine has demonstrated safety and immunogenicity in 5-month-old to 50-year-old Africans in multiple trials. Except for one, each trial has restricted enrollment to either infants and children or adults < 50 years old. This trial was conducted in Equatorial Guinea and assessed the safety, tolerability, and immunogenicity of three direct venous inoculations of 1.8 × 10 6 or 2.7 × 10 6 PfSPZ, of PfSPZ Vaccine, or normal saline administered at 8-week intervals in a randomized, double-blind, placebo-controlled trial stratified by age (6–11 months and 1–5, 6–10, 11–17, 18–35, and 36–61 years). All doses were successfully administered. In all, 192/207 injections (93%) in those aged 6–61 years were rated as causing no or mild pain. There were no significant differences in solicited adverse events (AEs) between vaccinees and controls in any age group ( P ≥ 0.17). There were no significant differences between vaccinees and controls with respect to the rates or severity of unsolicited AEs or laboratory abnormalities. Development of antibodies to P. falciparum circumsporozoite protein occurred in 67/69 vaccinees (97%) and 0/15 controls. Median antibody levels were highest in infants and 1–5-year-olds and declined progressively with age. Antibody responses in children were greater than in adults protected against controlled human malaria infection. Robust immunogenicity, combined with a benign AE profile, indicates children are an ideal target for immunization with PfSPZ Vaccine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Malaria, FalciparumMalaria VaccinesAnimalsAdultHumansChildInfantChild, PreschoolMiddle AgedPlasmodium falciparumSporozoitesVaccines, AttenuatedEquatorial GuineaDouble-Blind MethodImmunogenicity, Vaccine

Substanzen

Vaccines, AttenuatedMalaria Vaccines

Autor:innen und Institutionen

  • Ifakara Health Institute, Bagamoyo Research and Training Centre, Bagamoyo, Tanzania.
  • Ministry of Health and Social Welfare, Government of Equatorial Guinea, Malabo, Equatorial Guinea.
  • Sanaria Inc., Rockville, Maryland.
  • Swiss Tropical and Public Health Institute, Allschwil, Switzerland.
  • University of Basel, Basel, Switzerland.
  • Protein Potential LLC, Rockville, Maryland.

Zitieren

APA

Jongo, S. A., Urbano Nsue Ndong Nchama, V., Church, L. W. P., Olotu, A., Manock, S. R., Schindler, T., Mtoro, A., Kc, N., Devinsky, O., Zan, E., Hamad, A., Nyakarungu, E., Mpina, M., Deal, A., Bijeri, J. R., Ondo Mangue, M. E., Ntutumu Pasialo, B. E., Nguema, G. N., Rivas, M. R., …, & Hoffman, S. L. (2023). Safety and Immunogenicity of Radiation-Attenuated PfSPZ Vaccine in Equatoguinean Infants, Children, and Adults. The American Journal of Tropical Medicine and Hygiene, 109(1), 138-146. https://doi.org/10.4269/ajtmh.22-0773

Vancouver

Jongo SA, Urbano Nsue Ndong Nchama V, Church LWP, Olotu A, Manock SR, Schindler T, et al. Safety and Immunogenicity of Radiation-Attenuated PfSPZ Vaccine in Equatoguinean Infants, Children, and Adults. The American Journal of Tropical Medicine and Hygiene. 2023;109(1):138-146. doi:10.4269/ajtmh.22-0773

BibTeX
@article{Jongo2023,
  author = {Jongo, Said A and Urbano Nsue Ndong Nchama, Vicente and Church, L W Preston and Olotu, Ally and Manock, Stephen R and Schindler, Tobias and Mtoro, Ali and Kc, Natasha and Devinsky, Orrin and Zan, Elcin and Hamad, Ali and Nyakarungu, Elizabeth and Mpina, Maxmillian and Deal, Anna and Bijeri, José Raso and Ondo Mangue, Martin Eka and Ntutumu Pasialo, Beltrán Ekua and Nguema, Genaro Nsue and Rivas, Matilde Riloha and Chemba, Mwajuma and Ramadhani, Kamaka K and James, Eric R and Stabler, Thomas C and Abebe, Yonas and Riyahi, Pouria and Saverino, Elizabeth S and Sax, Julian and Hosch, Salome and Tumbo, Anneth and Gondwe, Linda and Segura, J Luis and Falla, Carlos Cortes and Phiri, Wonder Philip and Hergott, Dianna E B and García, Guillermo A and Maas, Carl and Murshedkar, Tooba and Billingsley, Peter F and Tanner, Marcel and Ayekaba, Mitoha Ondo'o and Sim, B Kim Lee and Daubenberger, Claudia and Richie, Thomas L and Abdulla, Salim and Hoffman, Stephen L},
  title = {Safety and Immunogenicity of Radiation-Attenuated PfSPZ Vaccine in Equatoguinean Infants, Children, and Adults},
  journal = {The American Journal of Tropical Medicine and Hygiene},
  year = {2023},
  volume = {109},
  number = {1},
  pages = {138--146},
  doi = {10.4269/ajtmh.22-0773}
}
Kostenlos starten →